Mesenchymal Stem Cell Therapy in Joint Disease
- Gregory Bock Organizer,
- Jamie Goode
Published Online: 7 OCT 2008
DOI: 10.1002/0470867973.ch7
Copyright © Novartis Foundation 2003
Book Title

Tissue Engineering of Cartilage and Bone: Novartis Foundation Symposium 249
Additional Information
How to Cite
Barry, F. P. (2008) Mesenchymal Stem Cell Therapy in Joint Disease, in Tissue Engineering of Cartilage and Bone: Novartis Foundation Symposium 249 (eds G. Bock and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470867973.ch7
Publication History
- Published Online: 7 OCT 2008
- Published Print: 11 MAR 2003
ISBN Information
Print ISBN: 9780470844816
Online ISBN: 9780470867976
- Summary
- Chapter
Summary
Mesenchymal stem cells have the capacity to differentiate into a variety of connective tissue cells including bone, cartilage, tendon, muscle and adipose tissue. These multipotent cells have been isolated from bone marrow and from other adult tissues including skeletal muscle, fat and synovium. Because of their multipotentiality and capacity for self renewal adult stem cells may represent units of active regeneration of tissues damaged as a result of trauma or disease. In certain degenerative diseases such as osteoarthritis (OA) stem cells are depleted, and have reduced proliferative capacity and reduced ability to differentiate. The delivery of stem cells to these individuals may therefore enhance repair or inhibit the progressive destruction of the joint. We have developed methods for the delivery of mesenchymal stem cell preparations taken from bone marrow to the injured knee joint. This treatment has the potential to stimulate regeneration of cartilage and retard the progressive destruction of the joint that typically occurs following injury.
